| Autor: |
Urzì Brancati V; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy., Scarpignato C; Department of Health Sciences, United Campus of Malta, MSD 2080 Msida, Malta.; Faculty of Medicine, Chinese University of Hong Kong, ShaTin, Hong Kong, China., Minutoli L; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy., Pallio G; Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy. |
| Abstrakt: |
Immunosuppressant drugs (ISDs) are routinely used in clinical practice to maintain organ transplant survival. However, these drugs are characterized by a restricted therapeutic index, a high inter- and intra-individual pharmacokinetic variability, and a series of severe adverse effects. In particular, genetic factors have been estimated to play a role in this variability because of polymorphisms regarding genes encoding for enzymes and transporters involved in the ISDs pharmacokinetic. Several studies showed important correlations between genetic polymorphisms and ISDs blood levels in transplanted patients; therefore, this review aims to summarize the pharmacogenetics of approved ISDs. We used PubMed database to search papers on pharmacogenetics of ISDs in adults or pediatric patients of any gender and ethnicity receiving immunosuppressive therapy after kidney transplantation. We utilized as search term: "cyclosporine or tacrolimus or mycophenolic acid or sirolimus or everolimus and polymorphism and transplant". Our data showed that polymorphisms in CYP3A5, CYP3A4, ABCB1, and UGT1A9 genes could modify the pharmacokinetics of immunosuppressants, suggesting that patient genotyping could be a helpful strategy to select the ideal ISDs dose for each patient. |
